Article Text

Download PDFPDF
Lack of scientific rationale for use of valproic acid for retinitis pigmentosa
  1. Michael A Sandberg,
  2. Bernard Rosner,
  3. Carol Weigel-DiFranco,
  4. Eliot L Berson
  1. Berman-Gund Laboratory for the Study of Retinal Degenerations, Harvard Medical School, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA
  1. Correspondence to Dr Michael A Sandberg, Berman-Gund Laboratory, Harvard Medical School, 243 Charles Street, Boston, MA 02114, USA; michael_sandberg{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

‘Therapeutic potential of valproic acid for retinitis pigmentosa,’ by Clemson et al,1 has significant flaws that militate against their conclusion that short-term valproic acid improved the vision of patients with retinitis pigmentosa.

The investigators should have performed a case–control study, comparing patients taking valproic acid with control patients matched for baseline field and acuity. …

View Full Text


  • Competing interests None.

  • Provenance and peer review Not commissioned; internally peer reviewed.